These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 30399387

  • 1. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS.
    J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
    [Abstract] [Full Text] [Related]

  • 2. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY.
    JAMA Dermatol; 2018 Sep 01; 154(9):1057-1061. PubMed ID: 30027278
    [Abstract] [Full Text] [Related]

  • 3. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS.
    J Am Acad Dermatol; 2018 Dec 01; 79(6):1081-1088. PubMed ID: 30025829
    [Abstract] [Full Text] [Related]

  • 4. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE, Fernández-Peñas P.
    Curr Probl Dermatol; 2018 Dec 01; 53():82-92. PubMed ID: 29131040
    [Abstract] [Full Text] [Related]

  • 5. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV.
    J Cutan Med Surg; 2021 Dec 01; 25(1):59-76. PubMed ID: 32746624
    [Abstract] [Full Text] [Related]

  • 6. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V.
    Am J Clin Dermatol; 2018 Jun 01; 19(3):345-361. PubMed ID: 29256113
    [Abstract] [Full Text] [Related]

  • 7. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
    Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M.
    J Am Acad Dermatol; 2020 Oct 01; 83(4):1130-1143. PubMed ID: 32360716
    [Abstract] [Full Text] [Related]

  • 8. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL.
    Am J Dermatopathol; 2017 Feb 01; 39(2):121-129. PubMed ID: 28134729
    [Abstract] [Full Text] [Related]

  • 9. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS.
    J Am Acad Dermatol; 2018 Dec 01; 79(6):1047-1052. PubMed ID: 29857011
    [Abstract] [Full Text] [Related]

  • 10. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P.
    J Am Acad Dermatol; 2016 Mar 01; 74(3):455-61.e1. PubMed ID: 26793994
    [Abstract] [Full Text] [Related]

  • 11. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
    Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN.
    JAMA Dermatol; 2016 Oct 01; 152(10):1128-1136. PubMed ID: 27411054
    [Abstract] [Full Text] [Related]

  • 12. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
    Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP.
    J Cutan Pathol; 2018 Jul 01; 45(7):504-507. PubMed ID: 29633300
    [Abstract] [Full Text] [Related]

  • 13. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions.
    Reschke R, Mockenhaupt M, Simon JC, Ziemer M.
    J Dtsch Dermatol Ges; 2019 Sep 01; 17(9):942-948. PubMed ID: 31210413
    [No Abstract] [Full Text] [Related]

  • 14. The life-threatening eruptions of immune checkpoint inhibitor therapy.
    Coleman EL, Olamiju B, Leventhal JS.
    Clin Dermatol; 2020 Sep 01; 38(1):94-104. PubMed ID: 32197753
    [Abstract] [Full Text] [Related]

  • 15. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
    Alniemi DT, Fischer A, Greene LA, Pierson JC.
    Dermatol Online J; 2018 Jul 15; 24(7):. PubMed ID: 30261564
    [Abstract] [Full Text] [Related]

  • 16. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR, File DM, Ziemer CM, Whang YE, Landman P, Googe PB, Collichio FA.
    J Immunother Cancer; 2019 Jan 08; 7(1):4. PubMed ID: 30621779
    [Abstract] [Full Text] [Related]

  • 17. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 08; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
    Sato M, Uhara H, Koga H, Okuyama R.
    J Dermatol; 2018 Oct 08; 45(10):e287-e289. PubMed ID: 29655228
    [No Abstract] [Full Text] [Related]

  • 19. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.
    Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG.
    J Cutan Pathol; 2017 Feb 08; 44(2):158-176. PubMed ID: 27859479
    [Abstract] [Full Text] [Related]

  • 20. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME.
    J Am Acad Dermatol; 2020 Nov 08; 83(5):1255-1268. PubMed ID: 32454097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.